ArticleEuropean radiology2026
CEST-MRI assessment of locally advanced pMMR rectal cancer for prediction of immune activation status following radiotherapy.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectivesTo evaluate whether chemical exchange saturation transfer MRI (CEST-MRI) enables early prediction of treatment response to subsequent immunochemotherapy following radiotherapy in patients with proficient mismatch repair (pMMR) locally advanced rectal cancer (LARC). MATERIALS AND
methodsIn this prospective single-center study, consecutive pMMR LARC patients, who underwent short-course radiotherapy followed by neoadjuvant immunochemotherapy and surgery, were enrolled between January 2024 and March 2025. Routine MRI and CEST-MRI were acquired at baseline and 1 week after radiotherapy. CEST-derived tumor metabolism and pH metrics were extracted, and absolute change (Δ) and percentage change (Δ%) were calculated. Patients with pathological complete response (pCR) were classified as good responders, while those with non-pCR were defined as poor responders. A multivariable model was constructed, and receiver-operating characteristic (ROC) curves were generated to evaluate diagnostic performance.
resultsForty patients (mean age, 56.8 ± 8.8 years; 24 men) were enrolled, 22 (55%) achieved pCR and 18 (45%) were non-pCR. CEST metrics showed significant differences between good responders and poor responders after radiotherapy. Based on multivariate logistic regression analysis, Δ% AACID
conclusionMetrics representing tumor metabolism and pH assessment by multiparametric CEST-MRI enable early prediction of treatment response to subsequent immunochemotherapy following radiotherapy in pMMR LARC, thereby informing early treatment decision-making. KEY POINTS: Question Noninvasive methods to capture early post-radiotherapy immune microenvironmental changes and predict response to subsequent immunochemotherapy in pMMR LARC remain unavailable. Findings Chemical exchange saturation transfer MRI can characterize tumor metabolism and pH and predict response to subsequent immunochemotherapy 1 week after radiotherapy in LARC. Clinical relevance Chemical exchange saturation transfer MRI provides an imaging-based, noninvasive biomarker for early post-radiotherapy response stratification in patients with pMMR LARC 1 week after radiotherapy, thereby informing timely treatment decisions for subsequent immunochemotherapy.
Indexed as
Identifiers
41935245What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.